Pam Elisabeth van der Meeren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pam Elisabeth van der Meeren has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Dave Sprengers
Erasmus MC Transplant Institute, University Medical Center Rotterdam, Department of Gastroenterology and Hepatology, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands
2 shared publications - Jan Nicolaas Maria Ijzermans
Erasmus MC Transplant Institute, University Medical Center Rotterdam, Department of Surgery, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands
2 shared publications Robert J. Porte
Erasmus MC Transplant Institute, University Medical Center Rotterdam, Department of Surgery
2 shared publications- Roeland Frederik de Wilde
Department of Surgery, Erasmus MC, Rotterdam, the Netherlands
2 shared publications Sverre Beijer
Erasmus MC Transplant Institute, University Medical Center Rotterdam, Department of Surgery
2 shared publicationsAlejandra Méndez Romero
Erasmus MC, University Medical Center Rotterdam, Department of Radiotherapy
1 shared publication
Latest Publications
- Open Access
- 24 October 2026
- Published by Elsevier in JHEP Reports
- p. 102075
Survival Outcomes in Hepatocellular Carcinoma: A Decade of Treatment in a Western Tertiary Referral Center
- 24 October 2026
- Published by Elsevier in JHEP Reports
- p. 102075
Open AccessSurvival Outcomes in Hepatocellular Carcinoma: A Decade of Treatment in a Western Tertiary Referral Center
- 19 June 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 82 (1) , 212-231
Benefit and harm of waiting time in liver transplantation for HCC
Liver transplantation is the most successful treatment for limited-stage HCC. The waiting time for liver transplantation (LT) can be a critical factor affecting the oncological prognosis and outcome of patients with HCC. Efficient strategies to optimize waiting time are essential to maximize the benefits of LT and to reduce the harm of delay in transplantation. The ever-increasing demand for donor livers emphasizes the need to improve the organization of the waiting list for transplantation and to optimize organ availability for patients with and without HCC. Current progress in innovations to expand the donor pool includes the implementation of living donor LT and the use of grafts from extended donors. By expanding selection criteria, an increased number of patients are eligible for transplantation, which necessitates criteria to prevent futile transplantations. Thus, the selection criteria for LT have evolved to include not only tumor characteristics but biomarkers as well. Enhancing our understanding of HCC tumor biology through the analysis of subtypes and molecular genetics holds significant promise in advancing the personalized approach for patients. In this review, the effect of waiting time duration on outcome in patients with HCC enlisted for LT is discussed.
- 19 June 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 82 (1) , 212-231
Benefit and harm of waiting time in liver transplantation for HCC
Liver transplantation is the most successful treatment for limited-stage HCC. The waiting time for liver transplantation (LT) can be a critical factor affecting the oncological prognosis and outcome of patients with HCC. Efficient strategies to optimize waiting time are essential to maximize the benefits of LT and to reduce the harm of delay in transplantation. The ever-increasing demand for donor livers emphasizes the need to improve the organization of the waiting list for transplantation and to optimize organ availability for patients with and without HCC. Current progress in innovations to expand the donor pool includes the implementation of living donor LT and the use of grafts from extended donors. By expanding selection criteria, an increased number of patients are eligible for transplantation, which necessitates criteria to prevent futile transplantations. Thus, the selection criteria for LT have evolved to include not only tumor characteristics but biomarkers as well. Enhancing our understanding of HCC tumor biology through the analysis of subtypes and molecular genetics holds significant promise in advancing the personalized approach for patients. In this review, the effect of waiting time duration on outcome in patients with HCC enlisted for LT is discussed.